<DOC>
	<DOCNO>NCT02157324</DOCNO>
	<brief_summary>This study evaluate safety efficacy combine use acalabrutinib ACP-319 , treatment chronic lymphocytic leukemia ( CLL )</brief_summary>
	<brief_title>Acalabrutinib Combination With ACP-319 , Treatment Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Men woman ≥ 18 year age confirm diagnosis CLL , relapse , refractory , ≥ 1 previous treatment CLL ; however , subject 17p deletion eligible relapse , refractory , 1 prior treatment CLL . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Agreement use contraception study 30 day last dose study drug sexually active able bear beget child . Prior malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer subject disease free ≥ 2 year limit survival &lt; 2 year . A lifethreatening illness , medical condition organ system dysfunction , investigator 's opinion , could compromise subject 's safety , interfere absorption metabolism acalabrutinib and/or ACP319 , put study outcome undue risk . Significant cardiovascular disease . Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel ulcerative colitis , symptomatic inflammatory bowel disease , partial complete bowel obstruction . Any immunotherapy within 4 week first dose study drug . For subject recent chemotherapy experimental therapy first dose study drug must occur 5 time halflife agent ( ) . History prior allogeneic bone marrow progenitor cell solid organ transplantation . Ongoing immunosuppressive therapy , include systemic enteric corticosteroid treatment CLL condition . Note : Subjects may use topical inhaled corticosteroid therapy comorbid condition . Central nervous system ( CNS ) involvement CLL . Grade ≥ 2 toxicity ( alopecia ) . Known history human immunodeficiency virus ( HIV ) active infection hepatitis C virus ( HCV ) hepatitis B virus ( HBV ) uncontrolled active systemic infection . Uncontrolled autoimmune hemolytic anemia idiopathic thrombocytopenia purpura . Absolute neutrophil count ( ANC ) &lt; 0.75 x 109/L platelet count &lt; 50 x 109/L unless due disease involvement bone marrow . Creatinine &gt; 1.5 x institutional upper limit normal ( ULN ) ; total bilirubin &gt; 1.5 x ULN ( unless due Gilbert 's disease ) ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 x ULN unless disease relate . Significant screen ECG abnormality include leave bundle branch block , 2nd degree AV block type II , 3rd degree block , Grade 2 high bradycardia , QTc &gt; 480 msec .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Bruton tyrosine kinase inhibitor</keyword>
	<keyword>Btk</keyword>
</DOC>